In Brief: Patent extensions
This article was originally published in The Tan Sheet
Executive Summary
Patent extensions: Provisions sought as amendments to Congress' omnibus appropriations bill -- including extensions for AHP's Lodine, SmithKline Beecham's Relafen and Schering-Plough's Claritin and Eulexin, and an amendment from Sen. Joseph Biden (D-Del.) that would have overturned the decision in Merck v. Kessler -- were not included in the continuing resolution. J&J's reimbursement request for Haldol Medicaid drug rebates also was not addressed by legislators before the Oct. 4 adjournment of the 104th Congress...